Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P, Nasdaq futures slip as markets await Iran sanctions, Nvidia results
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 7c ; Offers Guidance
May 2, 2024 6:01 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.07), $0.07 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $47.07 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of... More
